NasdaqCM · Biotechnology

Dermata Therapeutics (DRMA)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Buy+181.7%

$4.00 average target

$1.42+0.04 (+2.9%)Latest market snapshot · Yahoo Finance

Market cap$7.0M

Cash$4.4M

Quarterly burn$2.5M

Pipeline assets5

Short float1.6%

Latest coverage

News & Press Releases

External sources

Aug 21, 2026

Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial LaunchACCESS Newswire

Aug 17, 2026

Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq RulesACCESS Newswire

Aug 11, 2026

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026ACCESS Newswire

Continue with BioPharma ProUnlock 1 more recent stories and press releases.

Unlock Pro

Company profile

About Dermata Therapeutics

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.